 Rebecca Schweppe
Concepts (245)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thyroid Neoplasms | 23 | 2024 | 311 | 7.710 |
Why?
| | Proto-Oncogene Proteins B-raf | 11 | 2024 | 210 | 3.740 |
Why?
| | Thyroid Carcinoma, Anaplastic | 5 | 2023 | 35 | 2.360 |
Why?
| | src-Family Kinases | 4 | 2023 | 95 | 2.230 |
Why?
| | MAP Kinase Signaling System | 6 | 2024 | 314 | 1.680 |
Why?
| | Adenocarcinoma, Follicular | 4 | 2019 | 34 | 1.420 |
Why?
| | Focal Adhesion Kinase 1 | 4 | 2018 | 32 | 1.340 |
Why?
| | Dasatinib | 5 | 2023 | 54 | 1.160 |
Why?
| | Mutation | 11 | 2024 | 3706 | 1.100 |
Why?
| | Cell Line, Tumor | 19 | 2024 | 3185 | 1.080 |
Why?
| | MAP Kinase Kinase 1 | 2 | 2021 | 75 | 1.030 |
Why?
| | Protein Kinase Inhibitors | 7 | 2024 | 886 | 0.920 |
Why?
| | Drug Resistance, Neoplasm | 3 | 2018 | 753 | 0.890 |
Why?
| | Cell Culture Techniques | 4 | 2019 | 349 | 0.790 |
Why?
| | Cyclin-Dependent Kinase 4 | 1 | 2021 | 44 | 0.720 |
Why?
| | Cyclin-Dependent Kinase 6 | 1 | 2021 | 40 | 0.720 |
Why?
| | Neoplasm Transplantation | 5 | 2019 | 253 | 0.690 |
Why?
| | DNA, Neoplasm | 2 | 2013 | 154 | 0.680 |
Why?
| | Carcinoma | 3 | 2009 | 213 | 0.620 |
Why?
| | Crk-Associated Substrate Protein | 1 | 2018 | 5 | 0.620 |
Why?
| | Prolactin | 5 | 2003 | 97 | 0.610 |
Why?
| | Proto-Oncogene Proteins c-jun | 1 | 2018 | 52 | 0.610 |
Why?
| | Thyroid Diseases | 1 | 2018 | 35 | 0.600 |
Why?
| | Ethics, Research | 1 | 2018 | 31 | 0.600 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 2 | 2019 | 259 | 0.590 |
Why?
| | Neoplasm Proteins | 2 | 2013 | 417 | 0.560 |
Why?
| | Endocrinology | 1 | 2018 | 74 | 0.560 |
Why?
| | Neoplasm Metastasis | 4 | 2016 | 610 | 0.550 |
Why?
| | Telomerase | 2 | 2019 | 231 | 0.540 |
Why?
| | Mice, Nude | 7 | 2021 | 680 | 0.540 |
Why?
| | Melanoma | 3 | 2021 | 730 | 0.540 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2019 | 201 | 0.540 |
Why?
| | Protein-Tyrosine Kinases | 2 | 2019 | 431 | 0.510 |
Why?
| | Antineoplastic Agents | 4 | 2016 | 2045 | 0.510 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2019 | 503 | 0.460 |
Why?
| | Gene Expression Profiling | 3 | 2018 | 1686 | 0.460 |
Why?
| | Biomarkers, Tumor | 5 | 2021 | 1161 | 0.420 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2013 | 2062 | 0.410 |
Why?
| | Carcinoma, Papillary | 2 | 2014 | 77 | 0.410 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 1560 | 0.400 |
Why?
| | Gene Expression Regulation, Neoplastic | 5 | 2021 | 1327 | 0.390 |
Why?
| | Disease Models, Animal | 4 | 2019 | 4077 | 0.390 |
Why?
| | Cell Proliferation | 7 | 2021 | 2378 | 0.380 |
Why?
| | Thiazoles | 1 | 2012 | 118 | 0.370 |
Why?
| | Promoter Regions, Genetic | 7 | 2018 | 1213 | 0.360 |
Why?
| | DNA-Binding Proteins | 6 | 2014 | 1441 | 0.350 |
Why?
| | Humans | 33 | 2024 | 129847 | 0.340 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2021 | 808 | 0.330 |
Why?
| | Tumor Cells, Cultured | 6 | 2021 | 931 | 0.330 |
Why?
| | Bone Neoplasms | 1 | 2012 | 229 | 0.320 |
Why?
| | MAP Kinase Kinase 2 | 1 | 2009 | 28 | 0.320 |
Why?
| | Proto-Oncogene Proteins pp60(c-src) | 1 | 2009 | 12 | 0.310 |
Why?
| | Breast Neoplasms | 1 | 2021 | 2104 | 0.310 |
Why?
| | Animals | 20 | 2021 | 35409 | 0.310 |
Why?
| | Focal Adhesion Protein-Tyrosine Kinases | 1 | 2009 | 35 | 0.310 |
Why?
| | Iodine Radioisotopes | 2 | 2023 | 143 | 0.310 |
Why?
| | Pyrimidines | 1 | 2012 | 458 | 0.300 |
Why?
| | Protein Processing, Post-Translational | 3 | 2012 | 457 | 0.290 |
Why?
| | Proto-Oncogene Proteins | 3 | 2003 | 634 | 0.290 |
Why?
| | Benzodioxoles | 1 | 2009 | 106 | 0.290 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 2 | 2006 | 184 | 0.290 |
Why?
| | Mice | 10 | 2021 | 16983 | 0.280 |
Why?
| | Transcription Factors | 5 | 2014 | 1645 | 0.280 |
Why?
| | Cell Differentiation | 2 | 2014 | 1900 | 0.280 |
Why?
| | Signal Transduction | 8 | 2018 | 4935 | 0.280 |
Why?
| | Quinazolines | 1 | 2009 | 243 | 0.280 |
Why?
| | Apoptosis | 4 | 2021 | 2489 | 0.270 |
Why?
| | Cell Line | 5 | 2019 | 2780 | 0.270 |
Why?
| | Heterografts | 3 | 2016 | 134 | 0.270 |
Why?
| | Mitogen-Activated Protein Kinase 7 | 1 | 2006 | 21 | 0.260 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2006 | 151 | 0.240 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2006 | 284 | 0.230 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2006 | 274 | 0.220 |
Why?
| | Aurora Kinases | 1 | 2024 | 27 | 0.220 |
Why?
| | Early Growth Response Protein 1 | 1 | 2023 | 28 | 0.210 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2023 | 81 | 0.210 |
Why?
| | Fibronectins | 1 | 2023 | 127 | 0.200 |
Why?
| | Phenotype | 2 | 2023 | 3062 | 0.200 |
Why?
| | Phosphorylation | 7 | 2015 | 1716 | 0.190 |
Why?
| | Models, Biological | 2 | 2020 | 1724 | 0.190 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2023 | 434 | 0.180 |
Why?
| | Mass Spectrometry | 2 | 2009 | 717 | 0.180 |
Why?
| | Aminopyridines | 1 | 2021 | 98 | 0.170 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 2 | 2020 | 170 | 0.170 |
Why?
| | Pyrimidinones | 1 | 2021 | 102 | 0.170 |
Why?
| | Fibroblast Growth Factors | 2 | 2001 | 169 | 0.170 |
Why?
| | Proteins | 2 | 2003 | 944 | 0.170 |
Why?
| | Pyrroles | 1 | 2021 | 202 | 0.170 |
Why?
| | Pyridones | 1 | 2021 | 158 | 0.160 |
Why?
| | Validation Studies as Topic | 1 | 2019 | 21 | 0.160 |
Why?
| | Piperazines | 1 | 2021 | 339 | 0.150 |
Why?
| | Ethics, Professional | 1 | 2018 | 15 | 0.150 |
Why?
| | Professional Misconduct | 1 | 2018 | 12 | 0.150 |
Why?
| | Ethics Consultation | 1 | 2018 | 9 | 0.150 |
Why?
| | Ethics Committees, Research | 1 | 2018 | 41 | 0.150 |
Why?
| | NF-kappa B | 2 | 2014 | 666 | 0.150 |
Why?
| | Publications | 1 | 2018 | 41 | 0.150 |
Why?
| | Adrenal Cortex | 1 | 2018 | 27 | 0.140 |
Why?
| | Pituitary Gland, Anterior | 1 | 1997 | 39 | 0.140 |
Why?
| | Disease Susceptibility | 1 | 2020 | 334 | 0.140 |
Why?
| | Pyridines | 1 | 2021 | 478 | 0.140 |
Why?
| | Gene Expression Regulation | 4 | 2006 | 2545 | 0.140 |
Why?
| | Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2018 | 33 | 0.140 |
Why?
| | Fibroblast Growth Factor 2 | 1 | 1997 | 85 | 0.140 |
Why?
| | Genomics | 2 | 2020 | 716 | 0.140 |
Why?
| | Adrenal Cortex Neoplasms | 1 | 2018 | 60 | 0.130 |
Why?
| | Adrenocortical Carcinoma | 1 | 2018 | 63 | 0.130 |
Why?
| | Cell Growth Processes | 1 | 2016 | 51 | 0.130 |
Why?
| | Genes, ras | 1 | 2016 | 95 | 0.130 |
Why?
| | Pharmacogenomic Testing | 1 | 2016 | 61 | 0.120 |
Why?
| | Disease Management | 1 | 2020 | 592 | 0.120 |
Why?
| | Academic Medical Centers | 1 | 2018 | 483 | 0.120 |
Why?
| | Proto-Oncogene Proteins c-yes | 1 | 2015 | 3 | 0.120 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2019 | 486 | 0.120 |
Why?
| | Databases, Genetic | 1 | 2016 | 228 | 0.120 |
Why?
| | Female | 6 | 2021 | 68829 | 0.110 |
Why?
| | Heart Neoplasms | 1 | 2015 | 50 | 0.110 |
Why?
| | Cell Death | 1 | 2016 | 353 | 0.110 |
Why?
| | Carcinogenesis | 1 | 2016 | 214 | 0.110 |
Why?
| | Carcinoma, Papillary, Follicular | 1 | 2014 | 8 | 0.110 |
Why?
| | Thyroid Gland | 1 | 2014 | 95 | 0.110 |
Why?
| | Data Collection | 1 | 2016 | 653 | 0.100 |
Why?
| | Binding Sites | 3 | 2003 | 1251 | 0.100 |
Why?
| | Interleukin-8 | 1 | 2014 | 264 | 0.100 |
Why?
| | Genetic Variation | 1 | 2018 | 937 | 0.100 |
Why?
| | GA-Binding Protein Transcription Factor | 2 | 2003 | 5 | 0.100 |
Why?
| | Sirolimus | 1 | 2014 | 270 | 0.100 |
Why?
| | Neovascularization, Pathologic | 1 | 2014 | 297 | 0.100 |
Why?
| | Nitriles | 2 | 2010 | 169 | 0.090 |
Why?
| | Proto-Oncogene Protein c-ets-1 | 3 | 2003 | 19 | 0.090 |
Why?
| | Drug Evaluation, Preclinical | 2 | 2009 | 171 | 0.090 |
Why?
| | Cell Cycle Checkpoints | 1 | 2012 | 96 | 0.090 |
Why?
| | Proto-Oncogene Proteins c-ets | 3 | 2003 | 53 | 0.090 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2014 | 398 | 0.090 |
Why?
| | Tumor Burden | 1 | 2012 | 287 | 0.090 |
Why?
| | Enzyme Activation | 3 | 2009 | 813 | 0.090 |
Why?
| | Rats | 4 | 2006 | 5487 | 0.090 |
Why?
| | Enzyme Inhibitors | 3 | 2010 | 827 | 0.090 |
Why?
| | Protein Binding | 3 | 2009 | 2123 | 0.090 |
Why?
| | Cytostatic Agents | 1 | 2009 | 6 | 0.080 |
Why?
| | Butadienes | 1 | 2009 | 36 | 0.080 |
Why?
| | Cell Survival | 1 | 2012 | 1086 | 0.080 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 2009 | 191 | 0.080 |
Why?
| | Benzamides | 1 | 2009 | 203 | 0.070 |
Why?
| | Indoles | 2 | 2009 | 387 | 0.070 |
Why?
| | Neoplasm Invasiveness | 1 | 2010 | 484 | 0.070 |
Why?
| | Transfection | 4 | 2015 | 918 | 0.070 |
Why?
| | Prostatic Neoplasms | 1 | 2015 | 999 | 0.070 |
Why?
| | Reproducibility of Results | 2 | 2019 | 3089 | 0.070 |
Why?
| | Binding, Competitive | 2 | 2009 | 206 | 0.060 |
Why?
| | Colonic Neoplasms | 1 | 2008 | 241 | 0.060 |
Why?
| | Drug Delivery Systems | 1 | 2009 | 337 | 0.060 |
Why?
| | Sulfonamides | 1 | 2009 | 497 | 0.060 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2006 | 756 | 0.050 |
Why?
| | Molecular Sequence Data | 3 | 2003 | 2833 | 0.050 |
Why?
| | Sequence Analysis, Protein | 1 | 2003 | 28 | 0.050 |
Why?
| | Male | 5 | 2015 | 63759 | 0.050 |
Why?
| | RNA, Messenger | 2 | 2008 | 2703 | 0.050 |
Why?
| | Pituitary Neoplasms | 2 | 2001 | 180 | 0.050 |
Why?
| | Transcription Factor Pit-1 | 2 | 2003 | 24 | 0.050 |
Why?
| | Proteomics | 1 | 2009 | 1058 | 0.050 |
Why?
| | Pituitary Gland | 1 | 2003 | 148 | 0.050 |
Why?
| | Protein Subunits | 1 | 2003 | 233 | 0.050 |
Why?
| | Neoplasms | 1 | 2016 | 2454 | 0.050 |
Why?
| | Amino Acid Sequence | 2 | 2003 | 2057 | 0.050 |
Why?
| | Transcriptional Activation | 2 | 2003 | 366 | 0.050 |
Why?
| | RNA, Catalytic | 1 | 2002 | 185 | 0.050 |
Why?
| | Regulatory Sequences, Nucleic Acid | 1 | 2001 | 88 | 0.040 |
Why?
| | Isoenzymes | 1 | 2001 | 301 | 0.040 |
Why?
| | Protein Kinase C | 1 | 2001 | 262 | 0.040 |
Why?
| | Oligonucleotides | 1 | 2001 | 146 | 0.040 |
Why?
| | Transcription, Genetic | 1 | 2006 | 1416 | 0.040 |
Why?
| | Aged | 1 | 2019 | 22107 | 0.040 |
Why?
| | HeLa Cells | 1 | 2001 | 611 | 0.040 |
Why?
| | Hypoxia | 1 | 2006 | 1087 | 0.040 |
Why?
| | Quality Control | 1 | 2019 | 162 | 0.040 |
Why?
| | Toxicology | 1 | 2019 | 41 | 0.040 |
Why?
| | Luminescence | 1 | 2018 | 37 | 0.040 |
Why?
| | Ultraviolet Rays | 1 | 2001 | 383 | 0.040 |
Why?
| | Fibroblast Growth Factor 4 | 1 | 1997 | 19 | 0.040 |
Why?
| | Pharmacogenomic Variants | 1 | 2018 | 35 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-raf | 1 | 1997 | 45 | 0.040 |
Why?
| | DNA Mismatch Repair | 1 | 2018 | 47 | 0.040 |
Why?
| | Aldosterone | 1 | 2018 | 43 | 0.040 |
Why?
| | Middle Aged | 1 | 2019 | 31177 | 0.040 |
Why?
| | Oncogenes | 1 | 2018 | 110 | 0.030 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1997 | 182 | 0.030 |
Why?
| | Trans-Activators | 1 | 1999 | 392 | 0.030 |
Why?
| | Neoplasm Grading | 1 | 2018 | 283 | 0.030 |
Why?
| | Germ-Line Mutation | 1 | 2018 | 140 | 0.030 |
Why?
| | Gene Frequency | 1 | 2018 | 500 | 0.030 |
Why?
| | Catalysis | 1 | 1997 | 312 | 0.030 |
Why?
| | Cell Cycle Proteins | 1 | 1999 | 583 | 0.030 |
Why?
| | Tumor Suppressor Proteins | 1 | 2018 | 311 | 0.030 |
Why?
| | Information Storage and Retrieval | 1 | 2016 | 108 | 0.030 |
Why?
| | User-Computer Interface | 1 | 2016 | 149 | 0.030 |
Why?
| | Substrate Specificity | 2 | 2009 | 371 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2018 | 1201 | 0.030 |
Why?
| | Genetic Testing | 1 | 2018 | 422 | 0.030 |
Why?
| | Pharmacogenetics | 1 | 2016 | 172 | 0.030 |
Why?
| | NF-KappaB Inhibitor alpha | 1 | 2014 | 53 | 0.030 |
Why?
| | Neoplasm Staging | 1 | 2018 | 1282 | 0.030 |
Why?
| | Microsatellite Repeats | 1 | 2014 | 163 | 0.030 |
Why?
| | Homeodomain Proteins | 1 | 1997 | 493 | 0.030 |
Why?
| | I-kappa B Proteins | 1 | 2014 | 79 | 0.030 |
Why?
| | Computational Biology | 1 | 2018 | 593 | 0.030 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2014 | 102 | 0.030 |
Why?
| | DNA | 1 | 1999 | 1406 | 0.030 |
Why?
| | Autophagy | 1 | 2014 | 266 | 0.020 |
Why?
| | Disease Progression | 1 | 2018 | 2628 | 0.020 |
Why?
| | Cell Movement | 1 | 2015 | 950 | 0.020 |
Why?
| | Algorithms | 1 | 2018 | 1617 | 0.020 |
Why?
| | Oleanolic Acid | 1 | 2010 | 9 | 0.020 |
Why?
| | Interleukin-6 | 1 | 2014 | 724 | 0.020 |
Why?
| | Prognosis | 1 | 2018 | 3773 | 0.020 |
Why?
| | Sulfones | 1 | 2010 | 108 | 0.020 |
Why?
| | Mutant Proteins | 1 | 2009 | 100 | 0.020 |
Why?
| | Serum | 1 | 2009 | 58 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 954 | 0.020 |
Why?
| | Blotting, Western | 1 | 2010 | 1204 | 0.020 |
Why?
| | Adenosine Triphosphate | 1 | 2009 | 482 | 0.020 |
Why?
| | Phosphoproteins | 1 | 2009 | 333 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2014 | 4102 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2018 | 10241 | 0.010 |
Why?
| | Suppression, Genetic | 1 | 2003 | 25 | 0.010 |
Why?
| | Inflammation | 1 | 2014 | 2748 | 0.010 |
Why?
| | Genes, Dominant | 1 | 2003 | 94 | 0.010 |
Why?
| | Cell Extracts | 1 | 2002 | 17 | 0.010 |
Why?
| | Allosteric Regulation | 1 | 2002 | 94 | 0.010 |
Why?
| | Acetophenones | 1 | 2001 | 13 | 0.010 |
Why?
| | Culture Media, Serum-Free | 1 | 2001 | 49 | 0.010 |
Why?
| | Benzopyrans | 1 | 2001 | 25 | 0.010 |
Why?
| | Protein Kinase C-delta | 1 | 2001 | 44 | 0.010 |
Why?
| | Naphthalenes | 1 | 2001 | 57 | 0.010 |
Why?
| | United States | 1 | 2018 | 13913 | 0.010 |
Why?
| | Carbazoles | 1 | 2001 | 84 | 0.010 |
Why?
| | Immunoblotting | 1 | 2001 | 306 | 0.010 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2002 | 541 | 0.010 |
Why?
| | Adenoviridae | 1 | 2001 | 193 | 0.010 |
Why?
| | Cell-Free System | 1 | 1999 | 48 | 0.010 |
Why?
| | Protein Isoforms | 1 | 2001 | 393 | 0.010 |
Why?
| | Oncogene Proteins | 1 | 1999 | 54 | 0.010 |
Why?
| | Nucleic Acid Conformation | 1 | 2002 | 706 | 0.010 |
Why?
| | Base Sequence | 1 | 2002 | 2142 | 0.010 |
Why?
| | Time Factors | 1 | 2002 | 6550 | 0.010 |
Why?
|
|
Schweppe's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|